W
Wei Lei
Researcher at Shenyang Pharmaceutical University
Publications - 6
Citations - 237
Wei Lei is an academic researcher from Shenyang Pharmaceutical University. The author has contributed to research in topics: Photothermal therapy & Drug delivery. The author has an hindex of 4, co-authored 5 publications receiving 101 citations.
Papers
More filters
Journal ArticleDOI
Polydopamine-coated mesoporous silica nanoparticles for multi-responsive drug delivery and combined chemo-photothermal therapy.
TL;DR: The biodistribution and pharmacodynamics experiments of MSN-SS-PDA/DOX in 4T1 tumor models indicated that MSN/PDA made more DOX accumulate in tumor tissue than free DOX, extend circulation time of DOX in the body, and exhibit a significant synergistic antitumor efficacy.
Journal ArticleDOI
Gold nanoparticles modified hollow carbon system for dual-responsive release and chemo-photothermal synergistic therapy of tumor.
TL;DR: The results of this study indicated that DOX/HMC-Au@PEG has great potential in dual-triggered drug delivery and thermochemotherapy.
Journal ArticleDOI
Size effect on oral absorption in polymer-functionalized mesoporous carbon nanoparticles.
TL;DR: According to the data, the MPP nanoparticles could markedly improve the dissolution rate and oral bioavailability of Fen, and the rational design of an oral delivery system with respect to particle size is guided.
Journal ArticleDOI
Polydopamine-carbon dots functionalized hollow carbon nanoplatform for fluorescence-imaging and photothermal-enhanced thermochemotherapy.
TL;DR: In this paper, the NIR absorbing agent polydopamine (PDA) and carbon dots (CDs) were gated on the openings of hollow mesoporous carbon to construct a photothermal enhanced multi-functional system (HMC-SS-PDA@CDs).
Journal ArticleDOI
High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with mild hypercapnia: a multicenter randomized controlled trial
Jingen Xia,Sichao Gu,Wei Lei,Jihua Zhang,Huijing Wei,Chao Liu,Han Zhang,Rong-li Lu,Liqiong Zhang,Mingyan Jiang,Chao Hu,Zhenshun Cheng,Chaojie Wei,Yusheng Chen,Feng Lu,Min Chen,Honghao Bi,Hui Liu,C. Yan,Hong Teng,Yang Yang,Chen Liang,Yanlei Ge,Pengguo Hou,Jialin Liu,Weiwei Gao,Yi Zhang,Yingying Feng,Cheng Tao,Xu Huang,Pinhua Pan,Hong Luo,Chunmei Yun,Qingyuan Zhan +33 more
TL;DR: In this paper , a randomized controlled trial was conducted from July 2017 to December 2020 in 16 tertiary hospitals in China, where patients with acute COPD exacerbation with mild hypercapnia (pH ≥ 7.35 and arterial partial pressure of carbon dioxide > 45 mmHg) were randomly assigned to either HFNC or conventional oxygen therapy.